Q-Line Biotech Ltd. is stepping into the primary market with its maiden book-building IPO to raise Rs 214.48 crore at the upper price band. Operating in the in-vitro diagnostics sector since 2013, the company develops, manufactures, and supplies a diverse mix of reagents, kits, POC devices, and pathology equipment. Its core segments span clinical chemistry, haematology, immunodiagnostics, and molecular diagnostics. The business serves hospitals, medical colleges, and diagnostic chains directly as well as through a distribution network.
Over its 12-year history, the firm has built manufacturing capabilities and diversified its product lines. During the Covid-19 pandemic, it rolled out RT-PCR kits, RNA extraction kits, and VTM kits through a mix of internal R&D and technical collaborations with third-party institutes. As of March 31, 2026, the company employed 19 people in its R&D laboratories out of a total permanent payroll of 362 employees, alongside 223 contract workers.
Structure and Price Details of the Issue
The public issue consists entirely of a fresh issue of 62,53,200 equity shares with a face value of Rs 10 each. The price band is set at Rs 326 to Rs 343 per share. Investors must apply for a minimum lot of 800 shares, and in multiples of 400 shares thereafter. Based on the upper band, the cost of one single lot works out to Rs 2,74,400. The IPO opens for subscription on May 21, 2026, and closes on May 25, 2026, aiming for a listing on the NSE SME Emerge platform.
The company collected Rs 27.44 crore via a pre-IPO placement in May 2026 by issuing 8,00,000 shares at Rs 343 each. The total issue accounts for 26.81% of the post-IPO paid-up capital. Net proceeds will be deployed toward working capital requirements to the tune of Rs 93.50 crore, repayment or prepayment of specific borrowings amounting to Rs 90 crore, and general corporate needs. Hem Securities Ltd and Share India Capital Services Pvt. Ltd. are the joint lead managers, while Purva Sharegistry (India) Pvt. Ltd. acts as the registrar. Hem Finlease Pvt. Ltd. serves as the market maker and syndicate member.
Financial Performance and Earnings Quality
The company’s financial record displays strong top-line expansion coupled with noticeable bottom-line volatility. Total income and net profit stood at Rs 184.81 crore and Rs 32.10 crore for FY23, moving to Rs 206.45 crore and Rs 34.44 crore for FY24. For FY25, total income climbed to Rs 322.58 crore, but net profit dropped to Rs 28.13 crore following an extraordinary item of Rs 16.97 crore. For the nine-month period ended December 31, 2025, the firm posted a net profit of Rs 38.69 crore on a total income of Rs 236.50 crore.
This surge in pre-IPO earnings raises questions regarding sustainability. Furthermore, as of December 31, 2025, the company carried total borrowings of Rs 242.57 crore and contingent liabilities totaling Rs 61.64 crore, both of which require close monitoring. The firm has not paid any dividends across the reported periods of the offer document.
Valuation and Market Perspective
The company’s pre-IPO paid-up equity capital of Rs 17.07 crore will expand to Rs 23.33 crore after the issue. At the upper price band, the total market capitalization will be Rs 800.16 crore. The average EPS for the last two fiscals stands at Rs 25.00, with an average return on net worth of 23.17%. The issue is priced at a price-to-book value of 2.44 based on a net asset value of Rs 140.81 per share as of December 31, 2025, though post-IPO NAV data is omitted from the offer documents.
Attributing the bumper nine-month FY26 earnings to the fully diluted post-IPO equity results in a P/E ratio of 15.51, whereas the P/E based on FY25 earnings rises to 28.44. Because the company lists no direct peers in the offer document, it attempts to claim a premium valuation. The pricing looks full given the earnings fluctuations. Well-informed investors comfortable with SME segment risks may consider parking moderate funds for the long term.
Frequently Asked Questions
Q-Line Biotech Ltd. develops, manufactures, and markets a diverse range of diagnostic reagents, kits, POC devices, and consumables, and supplies diagnostic equipment to hospitals, medical colleges, and diagnostic service providers.
The price band for the IPO is set at Rs 326 to Rs 343 per equity share.
The minimum application must be made for 800 shares, and in multiples of 400 shares thereafter.
The company will utilize Rs 93.50 crore for working capital, Rs 90.00 crore for repayment or prepayment of certain borrowings, and the rest for general corporate purposes.
The IPO opens for subscription on May 21, 2026, and closes on May 25, 2026.
The shares will be listed on the NSE SME Emerge platform.
The issue is jointly lead managed by Hem Securities Ltd. and Share India Capital Services Pvt. Ltd.
